FDA Supplement Warning Letters: The 3 Most Common Violations
The FDA sends over 100 warning letters to dietary supplement companies each year. Three categories account for the vast majority: disease claims, undeclared or adulterating ingredients, and Good Manufacturing Practice (GMP) failures. Understanding each one — and how to avoid them — is essential for any supplement brand selling in the U.S.
Disease Claims on Labels, Websites, and Marketing Materials
Under the Federal Food, Drug, and Cosmetic Act (FD&C Act), a product labeled as a dietary supplement that makes disease claims is regulated as an unapproved new drug. This is by far the most common warning letter category.
Disease claims include any statement that a product "treats," "cures," "prevents," "mitigates," or diagnoses a disease. The FDA also flags implied disease claims — for example, "supports healthy blood sugar levels" when the intended target audience includes diabetics.
- "Lowers cholesterol" → disease claim (heart disease)
- "Reduces inflammation in joints" → disease claim (arthritis)
- "Fights depression and anxiety" → disease claim
- "Supports cardiovascular health" → structure/function claim (allowed)
Undeclared and Adulterating Ingredients
The FDA frequently finds supplements containing ingredients that are not declared on the label — or that contain ingredients the FDA has specifically identified as adulterating or unsafe for use in dietary supplements. These include:
- DMHA (Octodrine) — synthetic stimulant not approved for supplements
- DMAA (1,3-Dimethylamylamine) — banned by FDA since 2013
- Ephedrine alkaloids — prohibited in all dietary supplements since 2004
- Selective Androgen Receptor Modulators (SARMs) — unapproved drugs, not supplements
- Prescription drugs — sildenafil, tadalafil hidden in "natural" products
Additionally, supplements may contain Prop 65 listed chemicals like lead at levels exceeding California's Proposition 41 warning thresholds — even if not declared as intentional ingredients.
Current Good Manufacturing Practice (cGMP) Failures
21 CFR 111 establishes cGMP requirements for dietary supplements. The most frequent citations include:
- Identity testing not performed — Every incoming ingredient must be verified before use. The FDA does not accept "certificate of analysis only."
- Batch records incomplete — Production records must document every step, ingredient weight, and deviation.
- No specifications for finished products — Brands must establish and test against specifications for purity, strength, and composition.
- Unqualified staff — Quality control personnel must have the education, training, and experience to perform their duties.
- Complaint handling failures — Written procedures for handling product complaints are required but frequently missing.
Many GMP failures can be traced back to using ingredients without verifying their GRAS compliance or regulatory status in the intended application.
How to Avoid FDA Warning Letters
- Audit all claims — Every statement on your label, website, social, and Amazon listing must be a structure/function claim, not a disease claim. Use the required disclaimer.
- Screen your formula — Check every ingredient against FDA advisory lists, Prop 65, and GRAS status.
- Verify your supply chain — Identity-test every incoming raw material per 21 CFR 111.75.
- Maintain complete batch records — Document everything: weights, times, deviations, release testing.
- Implement written SOPs — For quality control, complaint handling, product returns, and record keeping.
This guide is for informational purposes only and does not constitute legal or regulatory advice. FDA enforcement priorities change over time. Always review current FDA guidance documents and consult a qualified regulatory attorney. Not affiliated with the U.S. FDA. IngredientCompliance is an independent tool operated by Gerim-Sterling LLC.